BGLC vs ECL · rev $9.5M vs P/E 35, rev $4.01B
BioNexus Gene Lab Corp Common stock (BGLC) versus Ecolab Inc (ECL) — a side-by-side from cached financials, not a winner call.
BioNexus Gene Lab Corp Common stock (BGLC) is a specialty chemicals company listed on NASDAQ.
Ecolab Inc (ECL) is a specialty chemicals company listed on US.
Latest reported BGLC revenue for 2024-12-31 was $9.5M. Net income was $1.6M. Revenue was down 2.7% from 2023-12-31 to 2024-12-31. BGLC currently screens at market cap $6.1M.
Latest reported ECL revenue for 2024-12-31 was $4.01B. Net income was $2.13B. Revenue was up 0.2% from 2024-09-30 to 2024-12-31. ECL currently screens at market cap $72.05B and trailing P/E 34.6.
BGLC currently screens at market cap $6.1M. ECL currently screens at market cap $72.05B and trailing P/E 34.6.
Not investment advice. Open the BGLC and ECL stock pages for the full models.
Not investment advice.